Tradestie Institutional Equity Comparison Engine

VRDN vs ZBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

VRDN Overall Edge

VRDN Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Viridian Therapeutics, Inc. Common Stock (VRDN) driven by superior Valuation, Growth & Margin, Momentum & Technical while ZBIO counters with relative strength in Options & Structure. Fundamentally, VRDN trades at 1.0x Forward P/E with -1781.4% operating margin (-63.5% YoY revenue) versus ZBIO at N/M Forward P/E and -2747.5% operating margin (-100.0% YoY). In options structure, VRDN sits in SURGE (16th %ile IV; Dealer Gamma Walls on Pro) against ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner VRDN
VRDN 1.0x vs ZBIO N/M Fwd P/E
Growth & Margin Winner VRDN
Op Margin -1781.4% vs -2747.5% ยท YoY -63.5% vs -100.0%
Momentum & Technical Winner VRDN
1Y +4.6% vs -21.7% ยท 52W Pos 79% vs 46%
Options & Structure Winner ZBIO
SURGE (16th %ile IV) vs CONSOLIDATION (13th %ile IV)
VRDN NASDAQ
Viridian Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$29.80
-3.47% 1D
Market Cap $3.5B
1M Return +56.59%
1Y Return +4.6%
Forward P/E 1.0x
Unified AI Score
36.8 / 100 SELL
Tech 50.0 Fund 32.0 Flow 65.0 Mom 40.0
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
1M Return +12.44%
1Y Return -21.68%
Forward P/E N/M
Unified AI Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: VRDN +4.6% ZBIO -21.68% Spread: +26.28 pp (VRDN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period VRDN Revenue ZBIO Revenue VRDN Op. Margin ZBIO Op. Margin Margin Edge
FY2018 $10M N/A -394.5% N/A VRDN
FY2019 $0M N/A -941.0% N/A VRDN
FY2020 $0M N/A -10512.4% N/A VRDN
FY2021 $0M N/A -2690.8% N/A VRDN
FY2022 $0M N/A -7579.2% N/A VRDN
FY2023 $0M $50M -81035.0% -74.3% ZBIO
FY2024 $0M $10M -99018.2% -3277.8% ZBIO
FY2025 $70M $10M -512.9% -3830.6% VRDN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: VRDN (7) vs ZBIO (2)
Institutional Metric VRDN ZBIO Criterion Row Winner
Market Capitalization Scale $3.5B $1.9B Larger Scale VRDN
Trailing P/E Ratio Valuation 1.0x N/M Lower Multiple VRDN
Forward P/E Ratio Valuation 1.0x N/M Lower Multiple VRDN
Revenue Growth (YoY) Growth -63.5% -100.0% Higher Growth VRDN
Operating Margin (TTM) Profitability -1781.4% -2747.5% Higher Margin VRDN
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -83.7% -265.1% Higher ROE VRDN
52-Week Range Position Momentum 79% ($13โ€“$34) 46% ($14โ€“$45) Stronger Trend VRDN
Beta / 30D Volatility Risk Regime 1.13ฮฒ ยท 65% Vol 1.16ฮฒ ยท 59% Vol Lower Realized Risk ZBIO
Unified Institutional Score Composite Signal 36.8 / 100 (SELL) 49.4 / 100 (HOLD) Higher Composite ZBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full VRDN vs ZBIO Buy Guide
VRDN SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live VRDN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ZBIO CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live ZBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither VRDN nor ZBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.